AstraZeneca may have used outdated info in coronavirus vaccine trial: US


 

Results from a US trial of AstraZeneca's COVID-19 vaccine may have used "outdated information," US federal health officials said in a statement early Tuesday.

Late Monday, the Data and Safety Monitoring Board said in a statement that it was concerned that AstraZeneca may have provided an incomplete view of the efficacy data.

Late Monday, the Data and Safety Monitoring Board said in a statement that it was concerned that AstraZeneca the included outdated information from that trial may have provided an incomplete view of the efficacy data.

AstraZeneca reported Monday that its COVID-19 vaccine provided strong protection among adults of all ages in a long-anticipated U.S. study, a finding that could help rebuild public confidence in the shot around the world and move it a step closer to clearance in the U.S.

In the study of 30,000 people, the vaccine was 79% effective at preventing symptomatic cases of COVID-19 including in older adults. Read More

Comments

Popular posts from this blog

Instagram adds group video call, new camera effects to app: How they work

3 Investment Strategies for Financial Independence!

G7 pledges 870 mn Covid vaccine doses, half to be delivered by 2021-end